Alnylam Pharmaceuticals, Inc. (ALNY): who owns it and who trades it
As of Nov 16, 2026, ALNY insiders reported 199 open-market sales worth $28.7M and 2 purchases worth $543K in the last 12 months, with 53% of the sale value made under pre-set 10b5-1 plans. The largest seller was Yvonne Greenstreet (CEO), with $8.8M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Alnylam Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and Congress mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ALNY
785 funds and institutions reported ALNY shares worth $40.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 11.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 15.02M | 11.33% | $4.5B | +3% |
| Capital World Investors | 11.14M | 8.40% | $3.4B | +3% |
| BlackRock, Inc. | 10.91M | 8.22% | $3.3B | +4% |
| Capital Research Global Investors | 9.75M | 7.35% | $2.9B | +3% |
| Vanguard Portfolio Management LLC | 6.54M | 4.93% | $2B | +1% |
| Vanguard Capital Management LLC | 6.03M | 4.55% | $1.8B | +1% |
| T. Rowe Price Investment Management, Inc. | 5.64M | 4.25% | $1.7B | +9% |
| Invesco Ltd. | 3.75M | 2.83% | $1.1B | +191% |
| State Street Corp | 3.56M | 2.68% | $1.1B | +7% |
| JPMorgan Chase & Co | 2.68M | 2.02% | $785M | – |
| Geode Capital Management, LLC | 2.64M | 1.99% | $791M | -1% |
| Baillie Gifford & Co | 2.44M | 1.84% | $734M | -2% |
| Norges Bank | 2.27M | 1.71% | $684M | – |
| Wellington Management Group LLP | 2.11M | 1.59% | $635M | +9% |
| Orbis Allan Gray Ltd | 1.99M | 1.50% | $598M | +49% |
| Dodge & Cox | 1.96M | 1.47% | $589M | +1% |
| Two Sigma Investments, LP | 1.88M | 1.41% | $565M | -6% |
| American Century Companies Inc | 1.85M | 1.40% | $558M | +3% |
| Clearbridge Investments, LLC | 1.26M | 0.95% | $379M | -7% |
| T. Rowe Price Associates | 1.15M | 0.87% | $346M | -20% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ALNY insiders reported $543K of open-market purchases and $28.7M of sales. 53% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Charles Elliott Sigal | Director | Purchase | 1,600 | $152.25 | $244K | Form 4 |
| Nov 9, 2026 | Amy W Schulman | Director | Purchase | 1,910 | $156.82 | $300K | Form 4 |
| Oct 2, 2026 | Bryan Supran | Vice president | Sale | 1,758 | $226.88 | $399K | Form 4 |
| Jun 1, 2026 | David E I Pyott | Director | Sale plan | 1,175 | $298.91 | $351K | Form 4 |
| Jun 1, 2026 | David E I Pyott | Director | Sale plan | 17 | $302.65 | $5.1K | Form 4 |
| Jun 1, 2026 | David E I Pyott | Director | Sale plan | 921 | $297.71 | $274K | Form 4 |
| Jun 1, 2026 | David E I Pyott | Director | Sale plan | 495 | $300.72 | $149K | Form 4 |
| Jun 1, 2026 | David E I Pyott | Director | Sale plan | 1,222 | $299.87 | $366K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 199 | $333.94 | $66.5K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 293 | $331.89 | $97.2K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 829 | $330.46 | $274K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 909 | $329.76 | $300K | Form 4 |
| Apr 6, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 56 | $320.14 | $17.9K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 209 | $318.47 | $66.6K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 265 | $316.61 | $83.9K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 359 | $317.44 | $114K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 8 | $325.49 | $2.6K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 81 | $323.64 | $26.2K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 86 | $319.69 | $27.5K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 224 | $321.64 | $72K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 245 | $322.86 | $79.1K | Form 4 |
| Apr 2, 2026 | Melissa McLaughlin | Chief Human Resources Of | Sale plan | 147 | $320.62 | $47.1K | Form 4 |
| Mar 5, 2026 | Pushkal Garg | Vice president | Sale plan | 500 | $326.08 | $163K | Form 4 |
| Mar 5, 2026 | Pushkal Garg | Vice president | Sale plan | 510 | $324.59 | $166K | Form 4 |
| Mar 5, 2026 | Pushkal Garg | Vice president | Sale plan | 740 | $323.55 | $239K | Form 4 |
| Mar 5, 2026 | Pushkal Garg | Vice president | Sale plan | 654 | $322.33 | $211K | Form 4 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 124 | $321.81 | $39.9K | Form 4 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 233 | $323.25 | $75.3K | Form 4 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 148 | $324.60 | $48K | Form 4 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 153 | $326.24 | $49.9K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 106 | $319.03 | $33.8K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 102 | $320.01 | $32.6K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 208 | $325.67 | $67.7K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 272 | $324.88 | $88.4K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 767 | $323.84 | $248K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 350 | $323.01 | $113K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 289 | $321.82 | $93K | Form 4 |
| Mar 4, 2026 | Pushkal Garg | Vice president | Sale plan | 215 | $320.81 | $69K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 973 | $323.84 | $315K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 444 | $323.01 | $143K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 368 | $321.82 | $118K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 274 | $320.81 | $87.9K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 265 | $325.67 | $86.3K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 135 | $319.03 | $43.1K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 345 | $324.88 | $112K | Form 4 |
| Mar 4, 2026 | Yvonne Greenstreet | CEO | Sale | 129 | $320.01 | $41.3K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 114 | $319.03 | $36.4K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 109 | $320.01 | $34.9K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 223 | $325.67 | $72.6K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 818 | $323.84 | $265K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 291 | $324.88 | $94.5K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 230 | $320.81 | $73.8K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 309 | $321.82 | $99.4K | Form 4 |
| Mar 4, 2026 | Jeffrey V. Poulton | CFO | Sale | 374 | $323.01 | $121K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 29 | $319.03 | $9.3K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 96 | $323.01 | $31K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 210 | $323.84 | $68K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 75 | $324.88 | $24.4K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 57 | $325.67 | $18.6K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 28 | $320.01 | $9K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 79 | $321.82 | $25.4K | Form 4 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 59 | $320.81 | $18.9K | Form 4 |
| Mar 3, 2026 | Pushkal Garg | Vice president | Sale plan | 355 | $316.74 | $112K | Form 4 |
| Mar 3, 2026 | Pushkal Garg | Vice president | Sale plan | 317 | $319.06 | $101K | Form 4 |
| Mar 3, 2026 | Pushkal Garg | Vice president | Sale plan | 640 | $320.48 | $205K | Form 4 |
| Mar 3, 2026 | Pushkal Garg | Vice president | Sale plan | 463 | $321.50 | $149K | Form 4 |
| Mar 3, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 289 | $316.55 | $91.5K | Form 4 |
| Mar 3, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 282 | $318.62 | $89.9K | Form 4 |
| Mar 3, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 722 | $320.51 | $231K | Form 4 |
| Mar 3, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 359 | $321.58 | $115K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 138 | $328.71 | $45.4K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 234 | $329.71 | $77.2K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 112 | $330.85 | $37.1K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 129 | $331.93 | $42.8K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 53 | $332.64 | $17.6K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 541 | $326.81 | $177K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 65 | $323.62 | $21K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 124 | $324.65 | $40.3K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 356 | $325.63 | $116K | Form 4 |
| Mar 2, 2026 | Jeffrey V. Poulton | CFO | Sale | 454 | $327.67 | $149K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 97 | $324.65 | $31.5K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 421 | $326.81 | $138K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 353 | $327.67 | $116K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 107 | $328.71 | $35.2K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 182 | $329.71 | $60K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 87 | $330.85 | $28.8K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 101 | $331.93 | $33.5K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 42 | $332.64 | $14K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 50 | $323.62 | $16.2K | Form 4 |
| Mar 2, 2026 | Pushkal Garg | Vice president | Sale plan | 277 | $325.63 | $90.2K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 37 | $332.64 | $12.3K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 94 | $331.93 | $31.2K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 81 | $330.85 | $26.8K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 170 | $329.71 | $56.1K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 100 | $328.71 | $32.9K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 329 | $327.67 | $108K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 392 | $326.81 | $128K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 258 | $325.63 | $84K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 90 | $324.65 | $29.2K | Form 4 |
| Mar 2, 2026 | Kevin Joseph Fitzgerald | Vice president | Sale plan | 47 | $323.62 | $15.2K | Form 4 |
Latest 100 of 201 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Yvonne Greenstreet | Chief Executive Officer, Director | – | $8.8M | Mar 4, 2026 |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | – | $8.5M | Mar 5, 2026 |
| Pushkal Garg | EVP Chief R&D | – | $5.4M | Mar 5, 2026 |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | – | $2.5M | Mar 4, 2026 |
| Melissa McLaughlin | Chief Human Resources Officer | – | $1.3M | Apr 6, 2026 |
| David E I Pyott | Director | – | $1.1M | Jun 1, 2026 |
| Tolga Tanguler | EVP, Chief Commercial Officer | – | $615K | Feb 13, 2026 |
| Bryan Supran | EVP, CLO and Secretary | – | $399K | Oct 2, 2026 |
| Amy W Schulman | Director | $300K | – | Nov 9, 2026 |
| Charles Elliott Sigal | Director | $244K | – | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALNY short interest
Low short interest. 4.1% of ALNY shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went up 1%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.47M ALNY shares were sold short, 4.1% of the shares outstanding, down 16.8% from the report before. At the average daily volume of 2.87M shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.47M | 4.08% | -17% | 2.87M | 1.9 |
| Oct 15, 2026 | 6.57M | 4.91% | -15% | 1.29M | 5.1 |
| Sep 30, 2026 | 7.71M | 5.76% | +7% | 1.20M | 6.5 |
| Sep 15, 2026 | 7.19M | 5.38% | +13% | 1.74M | 4.1 |
| Aug 31, 2026 | 6.34M | 4.74% | +33% | 1.63M | 3.9 |
| Aug 14, 2026 | 4.77M | 3.57% | -1% | 2.02M | 2.4 |
| Jul 31, 2026 | 4.80M | 3.59% | -17% | 2.20M | 2.2 |
| Jul 15, 2026 | 5.77M | 4.35% | -0% | 1.78M | 3.2 |
| Jun 30, 2026 | 5.80M | 4.37% | +7% | 1.37M | 4.2 |
| Jun 15, 2026 | 5.44M | 4.10% | +3% | 1.14M | 4.8 |
| May 29, 2026 | 5.30M | 4.00% | -2% | 917,637 | 5.8 |
| May 15, 2026 | 5.40M | 4.07% | +13% | 1.05M | 5.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ALNY
Since Nov 17, 2024, 2 members of Congress reported 0 purchases and 2 sales of ALNY. The latest was a sale by Cory A. Booker on Aug 11, 2026, reported Sep 9, 2026.
Purchases 0Sales 2
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Cory A. Booker (D-NJ) | Sale | $1K–$15K | Spouse | Sep 9, 2026 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Alnylam Pharmaceuticals company events
Alnylam Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026LeadershipAlnylam Pharmaceuticals, Inc. announced that Tolga Tanguler will depart from his role as the Company’s Executive Vice President, Chief Commercialization Officer in December 2026. Filing
- Oct 29, 2026ResultsReleased financial results. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- May 27, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 4, 2026LeadershipThe Board of Directors of Alnylam Pharmaceuticals, Inc. granted, following the recommendation of the People, Culture and Compensation Committee, a special equity award under the Company’s Second Amended and Restated 2018 Stock Incentive Plan to Yvonne Greenstreet, M.D., M.B.A., the Company’s Chief… Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 11, 2025AnnouncementAlnylam Pharmaceuticals, Inc. entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% convertible senior notes due 2027 to repurchase for cash approximately $34.4 million of the Notes for a total repurchase cost (including accrued and unpaid interest) of… Filing
- Dec 3, 2025LeadershipMichael W. Bonney and Carolyn Bertozzi, Ph.D. provided notice of each of their resignations from the Board of Directors of Alnylam Pharmaceuticals, Inc., effective on the same date. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Alnylam Pharmaceuticals financials
Famous investors that hold ALNY
3 of the 50 well-known investors we track reported holding ALNY in their latest 13F filing. The largest position is Israel Englander's, worth $93.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 377,728 | $93.2M | 0.1% | +20% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 28,463 | $7M | 0.0% | -71% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 907 | $224K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named ALNY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 7.5% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 7.5% |
| Nov 13, 2026 | Capital Research Global Investors | 13G/A | 8.2% |
| Nov 13, 2026 | Capital World Investors | 13G/A | 10.4% |
| Nov 13, 2026 | Capital Research Global Investors | 13G/A | 8.2% |
| Nov 13, 2026 | Capital World Investors | 13G/A | 10.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 9.5% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
Questions about Alnylam Pharmaceuticals, Inc. (ALNY) stock
Who owns the most ALNY stock?
The largest reported owner of Alnylam Pharmaceuticals, Inc. (ALNY) is FMR LLC (Fidelity), with 11.3% of the company. In total, 785 funds and institutions reported holding ALNY at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are ALNY insiders buying or selling?
In the last 12 months, ALNY insiders reported 2 open-market purchases worth $543K and 199 sales worth $28.7M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in ALNY?
As of Oct 30, 2026, 5.47M ALNY shares were sold short, 4.1% of the shares outstanding, down 16.8% from the report before. At the average daily volume of 2.87M shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Have members of Congress traded ALNY?
Yes. 2 members of Congress reported 0 purchases and 2 sales of ALNY since Nov 17, 2024. The latest was reported on Sep 9, 2026. See the trades.
Which famous investors hold ALNY?
3 of the 50 well-known investors we track reported ALNY in their latest 13F filing, including Israel Englander, Ray Dalio, Lee Ainslie. The largest position is worth $93.2M. See all holders.
Executive pay
Alnylam Pharmaceuticals's chief executive was paid a total of $14.9M for the year ended Dec 31, 2025, up 29% from $11.5M the year before. In the last 12 months, Alnylam Pharmaceuticals's executives and directors bought $543K of stock on the open market and sold $28.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.